Company / Revenue
iBio, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$225.0K
FY2025
5-year range
$0 / $2.4M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue returned to growth in FY2025 after 2 years of decline, reaching $225,000.
Based on SEC 10-K filings.
$225,000 in FY2025 with a 5-year CAGR of -35.5%.
Declined from $2M to $225,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -54.4%
- 5-Year CAGR
- -35.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -35.5%, indicating a declining trend.
- Peak revenue was recorded in FY2022.
- Lowest revenue in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.36 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $225.0K | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $1.9M | -20.5% |
| FY2022 | $2.4M | +44.7% |
| FY2021 | $1.6M | -18.8% |
| FY2020 | $2.0M | +354.5% |
| FY2019 | $444.0K | +12.7% |
| FY2018 | $394.0K | -58.4% |
| FY2017 | $948.0K | -48.8% |
| FY2016 | $1.9M | +802.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026